BioAtla (BCAB)
(Delayed Data from NSDQ)
$1.89 USD
+0.09 (5.00%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $1.89 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.89 USD
+0.09 (5.00%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $1.89 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
Zacks News
Does BioAtla, Inc. (BCAB) Have the Potential to Rally 114% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for BioAtla, Inc. (BCAB) points to an 114.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Can BioAtla, Inc. (BCAB) Climb 260% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for BioAtla, Inc. (BCAB) points to a 259.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
BioAtla, Inc. (BCAB) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
BioAtla, Inc. (BCAB) delivered earnings and revenue surprises of 10.39% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
BioAtla, Inc. (BCAB) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
BioAtla, Inc. (BCAB) delivered earnings and revenue surprises of -10% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of 0% and 27.42%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?